Development of this evidence summary
This evidence summary was developed for NICE by Bazian Ltd. The Interim process statement sets out the process NICE uses to select topics for the evidence summaries for unlicensed/off-label medicines and how the summaries are developed, quality assured and approved for publication.
Emma Chambers, Patient and Public Involvement Programme, NICE
Jason Miller, Pfizer
Richard Woodfield, MHRA
Professor Ian Roberts, Director, Clinical Trials Unit, London School of Hygiene & Tropical Medicine